Open AccessOptimizing therapy sequence to prevent patient attrition in EGFR mutation-positive advanced or metastatic NSCLC
Author(s) -
J. Roeper,
S Kurz,
Christian Grohé,
Frank Griesinger
Publication year - 2021
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2020-0854
Subject(s) - medicine , oncology , osimertinib , clinical trial , targeted therapy , acquired resistance , lung cancer , tyrosine kinase , systemic therapy , epidermal growth factor receptor , cancer , erlotinib , receptor , breast cancer
Clinical trial and real-world data in non-small-cell lung cancer indicate that 10–60% of patients that progressed on first- or second-generation EGFR-targeting tyrosine kinase inhibitors (TKI) do not receive systemic second-line therapy. In our article, we discuss efficacy, safety and treatment duration with different EGFR-TKIs and stress the need for delivery of the most efficacious therapy in the first-line. We also provide our perspective on analysis of circulating tumor DNA and the role of EGFR-TKI in combined therapies. Finally, we review new therapeutic options to overcome resistance to EGFR-TKI. We believe that overall treatment duration and access to different medications in subsequent lines of therapy should be considered when planning the optimal treatment strategy.